---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-26-004244"
form_type: "8-K"
ticker: "UEEC"
cik: "0001096938"
company_name: "United Health Products, Inc."
filed_at: "2026-07-10T16:19:24+00:00"
generated_at: "2026-07-10T16:20:04.716977+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# United Health Products partners with NAMSA to sponsor clinical study of CelluSTAT for FDA PMA

## Summary
- NAMSA will serve as regulatory sponsor, seeking an IDE to conduct a clinical study of CelluSTAT Hemostatic Gauze.
- UHP will hold exclusive right of reference to all study data for use in a revised PMA application.
- The study is part of efforts to resolve the outstanding FDA Warning Letter.
- NAMSA has decades of experience in clinical trial management for Class III hemostatic agents and FDA CDRH.
- CEO Brian Thom expressed confidence in NAMSA's ability to gain IDE approval and efficiently sponsor the study.

## SEC filing metadata
- accession: 0001477932-26-004244
- form_type: 8-K
- ticker: UEEC
- cik: 0001096938
- company_name: United Health Products, Inc.
- filed_at: 2026-07-10T16:19:24+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1096938/000147793226004244/0001477932-26-004244-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1096938/000147793226004244/ueec_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-26-004244
- JSON: https://secwatch.observer/filing/0001477932-26-004244.json
- Plain text: https://secwatch.observer/filing/0001477932-26-004244.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.